<DOC>
	<DOCNO>NCT00470093</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Interleukin-6 may stimulate white blood cell kill cancer cell . Giving interferon alfa together interleukin-6 may kill cancer cell . PURPOSE : This clinical trial study side effect well give interferon alfa together interleukin-6 work treat patient recurrent multiple myeloma .</brief_summary>
	<brief_title>Interferon Alfa Interleukin-6 Treating Patients With Recurrent Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient recurrent multiple myeloma treat recombinant interferon alfa recombinant interleukin-6 . - Determine safety optimal dose regimen patient . - Determine toxicity regimen patient . - Determine impact regimen clonogenic growth myeloma cell serial vitro assay . OUTLINE : This pilot study . Patients receive recombinant interferon alfa subcutaneously ( SC ) daily . Beginning 1 month later , patient also receive recombinant interleukin-6 SC daily . Treatment continue 6 month absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis recurrent multiple myeloma Must receive â‰¥ 2 prior therapy PATIENT CHARACTERISTICS : Performance status 03 PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>